The Saxenda® **Coverage Guide**

A guide to understanding cost and coverage for your patients

Novo Nordisk has developed a 3-step process to help identify patients with Saxenda® coverage and help those without coverage gain access.

Actor Portrayal.

Indications and Usage

Saxenda® (liraglutide) injection 3 mg is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in:

- Adult patients with an initial body mass index (BMI) of 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)
- Pediatric patients aged 12 years and older with body weight above 60 kg (132 lbs) and initial BMI corresponding to 30 kg/m^2 or greater for adults (obese) by international cut-offs

Limitations of Use

- Saxenda® contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist.
- The safety and effectiveness of Saxenda® in pediatric patients with type 2 diabetes have not been established.
- The safety and effectiveness of Saxenda® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS
Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. Saxenda® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of Saxenda® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda®.

novo nordisk®

Please see additional Important Safety Information throughout.
Please see Prescribing Information, including Boxed Warning, at https://www.novo-pi.com/saxenda.pdf.

Saxenda®
liraglutide injection 3mg

1 **Verify** pharmacy benefits

From SaxendaCoverage.com, you will be redirected to NovoCare® to verify your patient's pharmacy benefits

To use the website or receive live support, you may need your patient's pharmacy prescription card information. If your patient's plan includes Saxenda®, he or she may need to meet a minimum deductible before becoming eligible.

The benefits verification process has fewer data inputs and the ability to see estimated out-of-pocket costs for some patients, even if a prior authorization is required. Here you can:

- Check your patient's coverage status
- Use the co-pay calculator tool to estimate your patient's co-pay amount

If there is no co-pay amount listed and a PA is required, this means your patient has coverage but the co-pay amount is unknown.

If your patient does not have insurance coverage for Saxenda®, DO NOT start the PA process

If your patient's plan does not currently cover Saxenda®, here's what you can do:

- Write a letter to the benefits manager of your patient's human resources (HR) department to request coverage or provide an exception. A sample letter is available at Saxenda.com, or scan here:
- Have your patient check with their prescription insurance company to see if their coverage status has changed

Important Safety Information (cont'd)

Contraindications

Saxenda® is contraindicated in:

- Patients with a personal or family history of MTC or patients with MEN 2.
- Patients with a prior serious hypersensitivity reaction to liraglutide or to any of the excipients in Saxenda®.
- Pregnancy.

Please see additional Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at https://www.novo-pi.com/saxenda.pdf.

Saxenda® liraglutide injection 3mg

2 **Initiate** the PA process in the office

From SaxendaCoverage.com, you will be redirected to NovoCare® to initiate the PA process

Once you have verified your patient's benefits, only then should a prior authorization be initiated. Novo Nordisk partners with CoverMyMeds® to offer you a convenient way to navigate the PA process. The purpose of a PA is to identify appropriate patients based on their BMI, and should not be confused with a patient's individual coverage status. You can also initiate a PA by accessing an existing free CoverMyMeds.com account or creating a new one:

Visit CoverMyMeds.com

Call 1-866-452-5017

A follow-up PA may be reauthorized at or around the 4-month appointment period to verify that the patient has achieved at least 4% loss of baseline body weight

covermymeds®

Benefits of CoverMyMeds® ePA

- Process requests for any medication and all plans
- Receive faster PA determinations, often in real time
- Create PA renewals from previously submitted requests
- Available at no cost to providers and their staff
- Integrates with 500+ electronic health records

HubExpress℠
powered by covermymeds®

Benefits of HubExpress℠

- Keeps providers informed of PA status
- Offers appeal assistance, if needed
- Reduced paperwork and phone calls
- Enhanced communication with providers
- Dedicated support staff provides follow-up to move PA requests through to determination

Important Safety Information (cont'd)

Warnings and Precautions

- **Risk of Thyroid C-cell Tumors:** If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide postmarketing. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting). If pancreatitis is suspected, discontinue Saxenda® promptly and if pancreatitis is confirmed, do not restart.

Please see additional Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at https://www.novo-pi.com/saxenda.pdf.

Saxenda®
liraglutide injection 3mg

3 **Start** appropriate patients on Saxenda®

Direct patients to visit Saxenda.com to obtain and/or activate a Saxenda® Savings Card before heading to the pharmacy

Once the PA is approved, your patients are ready to fill their Saxenda® prescription (and a prescription for the NovoFine® 32G Tip needles). Give your patients a Saxenda® Sample Kit, which includes a Saxenda® Savings Card and a Saxenda® Patient Brochure. Contact your Novo Nordisk sales representative to receive a Patient Sample Kit.

Patients may pay as little as $25 or save up to $200 per Saxenda® prescription. *Maximum benefit of $200 per prescription, with 12 benefits annually*

Eligibility and other restrictions apply. Novo Nordisk reserves the right to modify or cancel this program at any time.

Patients paid $30 or less on 9 out of 10 prescriptions supported by the Saxenda® Affordability Program[1]

SaxendaCare®

When your patients activate a Saxenda® Savings Card online at SaxendaCoverage.com, they will automatically be enrolled in SaxendaCare®

SaxendaCare® offers your patients scientifically proven weight-loss and maintenance strategies through emails, calls from a coach, and more.

Actor Portrayal.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Acute Gallbladder Disease:** Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in patients treated with Saxenda® than with placebo even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.

Please see additional Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at https://www.novo-pi.com/saxenda.pdf.

Saxenda® liraglutide injection 3mg



Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Hypoglycemia:** Adult patients with type 2 diabetes on an insulin secretagogue (eg, a sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia with use of Saxenda®. The risk may be lowered by a reduction in the dose of insulin secretagogues or insulin. In pediatric patients without type 2 diabetes, hypoglycemia occurred. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms.
- **Heart Rate Increase:** Mean increases in resting heart rate of 2 to 3 beats per minute (bpm) were observed in patients treated with Saxenda®. Monitor heart rate at regular intervals and inform patients to report palpitations or feelings of a racing heartbeat while at rest during treatment with Saxenda®. Discontinue Saxenda® in patients who experience a sustained increase in resting heart rate
- **Renal Impairment:** Acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis, have been reported, usually in association with nausea, vomiting, diarrhea, or dehydration. Use caution when initiating or escalating doses of Saxenda® in patients with renal impairment.
- **Hypersensitivity Reactions:** Serious hypersensitivity reactions (eg, anaphylaxis and angioedema) have been reported in patients treated with liraglutide. If a hypersensitivity reaction occurs, patients should stop taking Saxenda® and promptly seek medical advice.
- **Suicidal Behavior and Ideation:** In adult clinical trials, 9 (0.3%) of 3,384 patients treated with Saxenda® and 2 (0.1%) of the 1,941 treated with placebo reported suicidal ideation; one of the Saxenda® treated patients attempted suicide. In a pediatric trial, 1 (0.8%) of the 125 Saxenda® treated patients died by suicide. There was insufficient information to establish a causal relationship to Saxenda®. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue treatment if patients experience suicidal thoughts or behaviors. Avoid Saxenda® in patients with a history of suicidal attempts or active suicidal ideation.

Adverse Reactions

- The most common adverse reactions, reported in ≥5% are nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis.

Drug Interactions

- Saxenda® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Saxenda®.

Use in Specific Populations

- There are no data on the presence of liraglutide in human breast milk; liraglutide was present in the milk of lactating rats.
- Saxenda® has not been studied in patients less than 12 years of age.
- Saxenda® slows gastric emptying. Saxenda® has not been studied in patients with preexisting gastroparesis.

Please see additional Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at https://www.novo-pi.com/saxenda.pdf.

Saxenda®
liraglutide injection 3mg

State of **AOM Coverage**

Anti-obesity medications (AOMs) are not universally covered by prescription drug plans. Here's why:

- **Medicare** currently does **not** cover AOMs
- **Medicaid** coverage is **limited** and is determined at the state level
- Many **commercial payers** offer AOM coverage as an **optional benefit** to their employer clients
- **Employers** can **opt in** to have AOM coverage added to their base health plan for their employees
- Coverage for AOMs **varies** by **employer** and typically requires a **prior authorization (PA)** to confirm that a patient's body mass index (BMI) is consistent with product labeling
- **Before submitting a PA**, **benefits verification** can help identify patients who have coverage for AOMs through their employer



*Decisions for Medicaid coverage are made on a state level.

Data on file. Novo Nordisk Inc; Plainsboro, NJ.

What is **NovoCare®**?

NovoCare® is a go-to resource for patient affordability and access.

It's important to make the affordability and access journey as seamless as possible so your patients can focus on treatment.



What does NovoCare® offer?

Benefit verification
Provides patient coverage status and estimated co-pay amount

Prior authorization assistance and appeals support
Incorporates CoverMyMeds® support services and online submission capabilities

Safe disposal resources
Provides patients with collection and disposal information for pens, vials, needles, and syringes

Co-pay card registration
Offers financial assistance to eligible patients*

Connections to educational resources
Provides access to comprehensive support resources for patients and health care professionals

*Eligibility and other restrictions apply and may be subject to change.

For patients who need additional support, live case managers are available at **NovoCare.com**

NOVOCARE®

Prescribing Saxenda® through your EHR system

Prescribe Saxenda® and NovoFine® 32G Tip needles through your EHR system, including the 4-week dose escalation, and schedule a 16-week follow-up visit.

ePrescribing Information

Saxenda®

- Form/strength: ***18 mg / 3 mL***
- Dispense quantity: ***5 x 3 mL per box***
- Dosage form: ***Solution, NDC 0169-2800-15***
- Dispense as written: ***Check the dispense as written (DAW) box***

NovoFine® 32G Tip needle

- Quantity: ***1 box (#100)***
- Dosage form: ***Disposable needles, NDC 0169-1851-89***

Starting on Saxenda® – disp: 5 pens

sig:	Week 1	0.6 mg SC once daily x 7 days
	Week 2	1.2 mg SC once daily x 7 days
	Week 3	1.8 mg SC once daily x 7 days
	Week 4	2.4 mg SC once daily x 7 days
	Week 5	3 mg SC once daily

Staying on Saxenda® – disp: 5 pens

sig: 3 mg SC once daily

EHR, electronic health record; SC, subcutaneous.

Visit ***SaxendaCoverage.com***

Novo Nordisk Insurance Reimbursement Hotline:

1-888-809-3942

(8:30 AM to 8:00 PM ET, Monday - Friday)

Please see Prescribing Information in Coverage Guide or at www.novo-pi.com/saxenda.pdf

Please see additional Important Safety Information throughout. Please see Prescribing Information, including Boxed Warning, at https://www.novo-pi.com/saxenda.pdf.

Reference: 1. Data on file. Novo Nordisk Inc; Plainsboro, NJ.

novo nordisk®

Saxenda®
liraglutide injection 3mg